Nona Biosciences

🌟 Join Nona Biosciences at World ADC 2024! 🌟 📍 Booth #417 🗓️ Presentation: Wednesday, November 6th ⏰ Time: 12:30 PM 🎤 Speaker: Musheng Bao, Vice President, Head of Biology Topic: Discovery and Preclinical Validation of a Novel Enzyme Cleavable Linker for Development of Next-Gen ADC Against Solid Tumors Summary: Tackling the challenges of poor drug penetration and high tumor heterogeneity in ADC and other biologics, Nona Bioscience has developed a groundbreaking linker technology. This innovative linker leverages a unique cleavage mechanism, utilizing an enzyme abundant in the tumor microenvironment (TME) of solid tumors. Paired with our proprietary payloads, it enables efficient, tumor-specific release, independent of internalization. Our preclinical data shows promising efficacy and safety improvements with this linker-payload system. Don’t miss this opportunity to learn about the next generation of targeted cancer therapies!

An overview of the 𝗛𝗖𝗔𝗯 𝗣𝗟𝗨𝗦™ by Nona Biosciences💡 HCAb PLUS™ is the world’s first fully human heavy chain-only antibody (HCAb) platform, clinically validated and experimentally proven, and enables breakthrough in therapeutic modalities. 𝗞𝗲𝘆 𝗙𝗲𝗮𝘁𝘂𝗿𝗲𝘀: 🌟 HBICE® Technology — Unleashing bispecifics, multispecifics, immunocytokines, and other cutting-edge formats with enhanced structure, size reduction, and chain simplicity. 🌟 Breakthrough Therapeutic Modalities — Designed for powerful applications in ADCs, RDCs, PROTACs, and other areas demanding precision, efficiency, and adaptability. 🌟 Superior Performance in CAR Therapies — HCAbs from our HCAb Harbour Mice® deliver reduced immunogenicity, high solubility, tissue penetration, and conjugation benefits, ideal for advanced CAR-based cell therapies. 🌟 Pioneering mRNA Therapies & Targeted Delivery — The compact size and structural benefits of HCAbs enable next-level mRNA designs and LNP modifications, opening up new avenues in targeted treatments. Nona Biosciences is leading the way with highly stable, low-immunogenic, fully human HCAbs for breakthrough therapies. Explore the future of therapeutic innovation with HCAb PLUS™: https://lnkd.in/ecfYaq5u #antibodies #fullyhuman #fullyhumanantibodies #HCAb #heavychainonlyantibodies #heavychainantibodies #nextgentherapeutics #Therapeutics #NonaBiosciences #HCAbPLUS #BiotechInnovation #ImmuneTherapy #ADC #mRNAtherapey #CARTtherapy #CART

Happy Friday, Everyone! 🎉 Let’s kick off the weekend with a behind-the-scenes look at how Nona's fully human Harbour Mice HCAb technology was created🐭 Swipe through the carousel to see more! From llamas to mice—Dr. Frank Grosveld, the visionary behind this technology, was inspired by the potential of VHH antibodies and set out to create fully human HCAbs using a transgenic mouse model. Discover how our HCAb Plus platform supports the development of next-gen biotherapeutic modalities: Learn More: https://lnkd.in/ecfYaq5u #HappyFriday #HarbourMice #Comic #fullyhuman #fullyhumanantibody #antibodies #VHH #singledomainantibody #HCAb #biotech #innovation

𝐆𝐞𝐭 𝐊𝐞𝐲 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐨𝐧 𝐁𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 (𝐛𝐬𝐀𝐛𝐬) 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐖𝐢𝐭𝐡 𝐎𝐮𝐫 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐀𝐬𝐬𝐚𝐲 Bispecific antibodies are engineered to bind two different antigens simultaneously, enabling more precise therapeutic interventions. This unique mechanism allows for innovative treatments in fields like oncology and immunotherapy, offering new hope for difficult-to-treat conditions. 💡 𝐇𝐨𝐰 𝐜𝐚𝐧 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐚𝐬𝐬𝐚𝐲 𝐜𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐞 𝐭𝐨 𝐭𝐡𝐞 𝐁𝐬𝐀𝐛 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐩𝐫𝐨𝐜𝐞𝐬𝐬? 🟧 Early risk identification: Developability assessment uncovers potential challenges such as stability, immunogenicity, and manufacturability issues early in the development process. 🔍 🔵 Increased success rates: Identifying risks upfront reduces development failures, allowing only the most promising bsAb candidates to advance, boosting the chances of creating safe, effective therapies. ✅ Learn more: https://lnkd.in/eQ2uhNrD #BispecificAntibodies #DevelopabilityAssay #Biotech #Oncology #Immunotherapy #DrugDevelopment #Pharma #PrecisionMedicine #Biologics #InnovativeTherapies #HealthcareInnovation

Last day at the Festival of Biologics. What an incredible time! We've had the pleasure of connecting with brilliant researchers from around the globe and showcasing the impact of our fully human #HarbourMice platform. Special thanks to Dr. Jiyong Zhang for his insightful presentation on how our HCAb Harbour Mice technology is driving biotherapeutic development forward. We're excited for the future of biologics—fully human is the way! 💡 #FestivalofBiologics #FOB #FOB2024 #FOB24 #AntibodyDiscovery #fullyhuman #fullyhumanantibodies #antibodies #antibody #Biotherapeutics #HCAb #heavychainonly #InnovationInScience #FutureOfMedicine #LifeSciences #Biotech

Day 1 at the Festival of Biologics! What an amazing start to the event! We’re excited to already connect with so many of you at Booth #736. If you haven't dropped by yet, there is still time to do it and learn about how our HCAb technology is shaping the future of biotherapeutic development. 📢 And don't forget to join Dr. Jiyong Zhang, Nona’s Chief Business Officer, for an insightful session on the latest advancements in immunotherapy using our HCAb Harbour Mice® platform. 🗓️ When: Tomorrow Oct 16 at 9:35 am You won’t want to miss this exciting talk! Let’s continue making breakthroughs together. #FestivalofBiologics #FOB #FOB2024 #HCAb #antibodies #biotherapeutics #Biotech #fullyhuman #CART #ADC #multispecific #bispecific #immunotherapy #Tcellengager #TCE

The Festival of Biologics is just around the corner, taking place next week from October 15-17 in Basel! We’re thrilled to be a Diamond Sponsor this year, and you can find us at Booth #736. Don’t miss the opportunity to learn how our HCAb technology can transform your biotherapeutic development. Also, make sure to catch Dr. Jiyong Zhang, Nona’s Chief Business Officer, as he shares the latest innovations in immunotherapy using our HCAb platform. It’s a session you won’t want to miss! Learn more about our HCAb Harbour Mice® platform: https://lnkd.in/dfgdKMeH #FestivalofBiologics #FOB #FOB2024 #HCAb #antibodies #biotherapeutics #Biotech #fullyhuman #CART #ADC #multispecific #bispecific #immunotherapy #Tcellengager #TCE

We're pleased to announce Nona Biosciences' strategic collaboration with OverT Bio! By leveraging Nona's fully human HCAb Harbour Mice® platform and the NonaCarFx™ platform, along with OverT Bio's innovative approaches, we aim to advance next-generation cell therapies for solid tumors. The fully human heavy chain-only antibodies (HCAbs) generated from Nona's HCAb Harbour Mice® platform offer an ideal modality for CAR-based cell therapies. Unlike traditional methods, these HCAbs have the potential to significantly reduce immunogenicity. Their compact size, simplified structure, and precisely calibrated binding properties provide enhanced versatility in CAR design. With these advantages, we're poised to drive the future of cell therapy and offer new hope to patients battling solid tumors. Stay tuned for more updates on this exciting partnership! Learn more: https://lnkd.in/geCKdqpA #NonaBiosciences #HarbourMice #CART #oncology

Big News in Science! Congratulations to Victor Ambros and Gary Ruvkun, the winners of the 2024 Nobel Prize in Physiology or Medicine. Their groundbreaking discovery of microRNA has revolutionized our understanding of gene regulation. By uncovering how microRNA controls gene expression after transcription, they’ve opened new avenues for research and therapies targeting diseases such as cancer and autoimmune diseases. At Nona Biosciences, we’re at the forefront of therapeutic innovation. Our services focus on the discovery and development of fully human antibodies that are hyper-targeted, ensuring precise therapeutic interventions for a range of diseases. Discover more: https://lnkd.in/dfgdKMeH #NobelPrize #Science #Medicine #microRNA #GeneRegulation #Biotech #Antibodydiscovery #TargetedTherapies #fullyhuman #antibodies

CD3-based bispecific antibodies are transforming cancer treatment and showing promise for autoimmune diseases. Nona Biosciences’ HBICE® platform leverages Heavy Chain Only Antibodies (HCAbs) to enhance tumor targeting and immune cell activation. Explore how the HBICE® platform optimizes T Cell Engager (TCE) cytotoxicity while minimizing risks like cytokine release syndrome (CRS). Key Learning Objectives: ✅ Understand TCEs' role in cancer therapy ✅ Dive into the MOA of CD3 TCEs ✅ Discover the potential of CD3 HBICE® for solid tumors with fewer adverse events 👉 Learn more: https://lnkd.in/eFBC6Mid #Immunotherapy #CancerTreatment #Biotechnology #TCellEngagers #NonaBiosciences #HBICE #Oncology #AutoimmuneTherapy